From the Research
The initial treatment for non-specific interstitial pneumonia (NSIP) typically involves corticosteroids, with prednisone being the first-line medication, as supported by the most recent and highest quality study available 1.
Treatment Approach
The treatment approach for NSIP involves the use of immunosuppressive agents to manage the disease.
- Corticosteroids, such as prednisone, are the primary treatment for NSIP, with a typical starting dose of 0.5-1 mg/kg/day (approximately 40-60 mg daily for an average adult) 1.
- The dose is maintained for 4-12 weeks, after which it is gradually tapered over several months, depending on the clinical response 1.
- For patients who do not respond adequately to corticosteroids or experience significant side effects, immunosuppressive agents such as azathioprine, mycophenolate mofetil, or cyclophosphamide may be added as steroid-sparing agents 1.
Supportive Care
Supportive care is also essential in the management of NSIP, including:
- Supplemental oxygen for patients with hypoxemia
- Pulmonary rehabilitation
- Vaccination against influenza and pneumococcal pneumonia
Monitoring Treatment Efficacy
Treatment efficacy should be monitored through:
- Pulmonary function tests
- Radiographic imaging
- Symptom assessment As noted in the study by 1, corticosteroids are effective in NSIP because they suppress the inflammatory response and immune system activation that contribute to lung damage in this condition. The most recent study 1 provides the highest quality evidence for the treatment of NSIP, and its findings should be prioritized in clinical decision-making.